U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H22FN5O3.C6H6O3S
Molecular Weight 581.615
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SPEBRUTINIB BESYLATE

SMILES

OS(=O)(=O)C1=CC=CC=C1.COCCOC2=CC=C(NC3=NC=C(F)C(NC4=CC(NC(=O)C=C)=CC=C4)=N3)C=C2

InChI

InChIKey=ABSXPNGWJFAPRT-UHFFFAOYSA-N
InChI=1S/C22H22FN5O3.C6H6O3S/c1-3-20(29)25-16-5-4-6-17(13-16)26-21-19(23)14-24-22(28-21)27-15-7-9-18(10-8-15)31-12-11-30-2;7-10(8,9)6-4-2-1-3-5-6/h3-10,13-14H,1,11-12H2,2H3,(H,25,29)(H2,24,26,27,28);1-5H,(H,7,8,9)

HIDE SMILES / InChI

Molecular Formula C6H6O3S
Molecular Weight 158.175
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C22H22FN5O3
Molecular Weight 423.4402
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Spebrutinib (CC-292, AVL-292) is a selective inhibitor of BTK that was under clinical development for the treatment of rheumatoid arthritis (phase II) and B-cell Lymphoma (phase I). The drug was discovered by Avila Therapeutics, but then acquired by Celgene. Spebrutinib covalently binds to Cys 481 in BTK, blocking the ATP-binding pocket of the enzyme. The drug is no longer in Celgene's pipeline and its development is supposed to be terminated.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
5.9 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Unknown

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.
2012 Jul
Patents

Sample Use Guides

Patients should take oral spebrutinib in a dose of 375 mg daily (250 mg in the AM and 125 mg in the PM for 28 days).
Route of Administration: Oral
Cells from the Ramos lymphoma cell line, which expresses an intact BCR signaling pathway, were treated with increasing concentrations of spebrutinib for 1 hour and lysed, and the percent occupancy of BTK was determined with ELISA. The concentration of spebrutinib required for 50% occupancy was 5.9 nM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 19:44:26 GMT 2023
Edited
by admin
on Fri Dec 15 19:44:26 GMT 2023
Record UNII
RC3ET192UJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SPEBRUTINIB BESYLATE
USAN  
USAN  
Official Name English
AVL-292 BESYLATE
Code English
2-PROPENAMIDE, N-(3-((5-FLUORO-2-((4-(2-METHOXYETHOXY)PHENYL)AMINO)-4-PYRIMIDINYL)AMINO)PHENYL)-, BENZENESULFONATE (1:1)
Systematic Name English
SPEBRUTINIB BESILATE
WHO-DD  
Common Name English
Spebrutinib besilate [WHO-DD]
Common Name English
CC-292 BESYLATE
Code English
SPEBRUTINIB BESYLATE [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C124801
Created by admin on Fri Dec 15 19:44:26 GMT 2023 , Edited by admin on Fri Dec 15 19:44:26 GMT 2023
NCI_THESAURUS C129825
Created by admin on Fri Dec 15 19:44:26 GMT 2023 , Edited by admin on Fri Dec 15 19:44:26 GMT 2023
Code System Code Type Description
FDA UNII
RC3ET192UJ
Created by admin on Fri Dec 15 19:44:26 GMT 2023 , Edited by admin on Fri Dec 15 19:44:26 GMT 2023
PRIMARY
ChEMBL
CHEMBL3301625
Created by admin on Fri Dec 15 19:44:26 GMT 2023 , Edited by admin on Fri Dec 15 19:44:26 GMT 2023
PRIMARY
NCI_THESAURUS
C141425
Created by admin on Fri Dec 15 19:44:26 GMT 2023 , Edited by admin on Fri Dec 15 19:44:26 GMT 2023
PRIMARY
USAN
AB-95
Created by admin on Fri Dec 15 19:44:26 GMT 2023 , Edited by admin on Fri Dec 15 19:44:26 GMT 2023
PRIMARY
CAS
1360053-81-1
Created by admin on Fri Dec 15 19:44:26 GMT 2023 , Edited by admin on Fri Dec 15 19:44:26 GMT 2023
PRIMARY
SMS_ID
100000175202
Created by admin on Fri Dec 15 19:44:26 GMT 2023 , Edited by admin on Fri Dec 15 19:44:26 GMT 2023
PRIMARY
PUBCHEM
74892828
Created by admin on Fri Dec 15 19:44:26 GMT 2023 , Edited by admin on Fri Dec 15 19:44:26 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY